ANLOTINIB ORAL COMBINADO CON IRINOTECAN ... ¡ UNA OPCIÓN SUPERIOR PARA EL TRATAMIENTO DE SEGUNDA LÍNEA DEL SMALL CELL LUNG CANCER EXTENSIVE-STAGE CON RECAÍDA EN SEIS MESES !!! . POST BY " LUNG CANCER " . PARA EL Dr. STEPHEN V LIU ... EL TRATAMIENTO DE 2a LINEA ESTANDAR ES YA ... EL TARLATAMAB .

RESPECTO A ESTOS RESULTADOS DE SEGUNDA LÍNEA CON ANLOTINIB ORAL ... Y PUBLICADOS POR LA PRESTIGIOSA  REVISTA  " LUNG CANCER " ... STEPHEN V LIU SE HACE ECO DE ELLOS Y LO MAS CURIOSO ES QUE LIU " YA SOLO CONTEMPLA AL TARLATAMAB DE AMGEN ... COMO TRATAMIENTO ESTÁNDAR PARA SEGUNDA LINEA " ... DESPUES DE QUE TARLATAMAB HAYA  SUPERARADO AMPLIAMENTE AL LURBINECTEDIN EN LA FASE III CONFIRMATORIA : DELPHI304 ... TAL Y COMO MOSTRÓ Y DEMOSTRÓ EN ASCO25 .

Link : https.vucykb##.pj 

ANLOTINIB ORAL y/o QUIMIOTERAPIA Tienen una Eficacia Prometedora y una Toxicidad Manejable Como Terapia de SEGUNDA LÍNEA del SMALL CELL LUNG CANCER EXTENSIVE-STAGE .

Highlights 

• ANLOTINIB And IRINOTECAN Achieved ORR 62.2% And DCR 91.9% As SECOND-LINE Therapy FOR SMALL CELL LUNG CANCER EXTENSIVE-STAGE  .

• Patients With 3 < CTFI ≤ 6 Months Had Longer PFS And OS .

• Previous IMMUNOTHERAPY Did Not Affect The Efficacy Of ANLOTINIB And IRINOTECAN .

Results :

Thirty-Seven Patients Were Evaluable For Efficacy And Safety Profile. ORR Was 62.2 % (23/37) And DCR Was 91.9 % (34/37). Median PFS and OS For All The Patients Were 4.5 And 7.2 Months .

PFS And OS Of Patients With a 3 < Chemothrerapy-Free Survival (CTFI) ≤ 6 Months Were Better Than Those Of Patients With a CTFI ≤ 3 Months ( PFS 6.5 vs 3.9 Months, P = 0.0073; OS 18.5 vs 5.9 Months, P < 0.001 ) .

 Patients who previously received chemotherapy alone or chemotherapy combined with immunotherapy as first-line treatment had similar median PFS and OS (mPFS 4.4 vs 4.9 months, P = 0.38; mOS 7.2 vs 8.3 months, P = 0.79) .

Only Three Patients ( 8.5 % ) Suffered From Grade 3 Adverse Effects, Which Were Thrombocytopenia, Leukopenia, And Anemia .

CONCLUSIÓN :

The Combination Of ANLOTINIB and IRINOTECAN as SECOND-LINE Treatment For ES-SCLC Patients Who RELAPSED Within 6 Months Demonstrated Promising Efficacy And Had Manageable Toxicities .

 Patients With 3 < CTFI ≤ 6 Months Had Longer PFS And OS Than Those With CTFI ≤ 3 Months .

 Previous IMMUNOTHERAPY Did Not Affect The Efficacy Of Subsequent ANLOTINIB And IRINOTECAN. It May Become a Novel Therapeutic Strategy For This Population .